Chinook Therapeutics KDNY

$ 40.39 0.0%

Quarterly report 2023-Q2
added 08-07-2023

Chinook Therapeutics Balance Sheet 2011-2024 | KDNY

Annual Balance Sheet Chinook Therapeutics

	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-76 M	-138 M	-	-59.6 M	-	-	-	-	-	-	-	-
Long Term Debt	34.5 M	39.6 M	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	4.95 M	4.4 M	3.04 M	1.8 M	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	940 K	-	-	-	-	-	-	-	-
Total Current Liabilities	50.8 M	40.1 M	22.8 M	21.6 M	30.5 M	41.4 M	30.6 M	31.1 M	-	-	-	-
Total Liabilities	132 M	110 M	94.4 M	226 M	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	6.95 M	-	-	-	-	-	-	-	-
Retained Earnings	-420 M	-232 M	-	-	-	-	-	-	-	-	-	-
Total Assets	574 M	564 M	429 M	291 M	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	115 M	182 M	188 M	59.6 M	126 M	158 M	74.9 M	150 M	119 M	8.53 M	-	-
Book Value	442 M	454 M	335 M	65.6 M	-	-	-	-	-	-	-	-
Total Shareholders Equity	442 M	454 M	335 M	-41.1 M	135 M	237 M	227 M	262 M	-61.3 M	-38.8 M	-	-

All numbers in USD currency

Quarterly Balance Sheet Chinook Therapeutics

	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	29.7 M	33.2 M	34.5 M	35.8 M	37.2 M	38.5 M	39.6 M	40.8 M	37.1 M	38 M	38.7 M	38.7 M	38.7 M	38.7 M	114 K	31.6 M	31.6 M	31.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	132 M	131 M	132 M	116 M	94.1 M	104 M	110 M	114 M	111 M	98.3 M	94.4 M	94.4 M	94.4 M	94.4 M	37 M	226 M	226 M	226 M	222 M	222 M	222 M	222 M	208 M	208 M	208 M	208 M	211 M	211 M	211 M	211 M	220 M	220 M	220 M	220 M	47.8 M	47.8 M	47.8 M	47.8 M	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	95 K	95 K	95 K	95 K	6.95 M	16 M	6.95 M	6.95 M	16 M	16 M	16 M	14.9 M	14.9 M	14.9 M	14.9 M	15 M	15.1 M	15.1 M	15.1 M	15.1 M	15 M	15 M	15 M	15 M	33.4 M	33.4 M	33.4 M	33.4 M	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-547 M	-480 M	-420 M	-357 M	-301 M	-263 M	-232 M	-239 M	-209 M	-166 M	-129 M	-129 M	-129 M	-129 M	-47.2 M	-487 M	-487 M	-487 M	-405 M	-405 M	-405 M	-405 M	-284 M	-284 M	-284 M	-284 M	-192 M	-192 M	-192 M	-192 M	-101 M	-101 M	-101 M	-101 M	-61.6 M	-61.6 M	-61.6 M	-61.6 M	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	489 M	544 M	574 M	590 M	601 M	531 M	564 M	383 M	408 M	399 M	429 M	429 M	429 M	429 M	15.7 M	291 M	291 M	291 M	358 M	358 M	358 M	358 M	445 M	445 M	445 M	445 M	439 M	439 M	439 M	439 M	482 M	482 M	482 M	482 M	126 M	126 M	126 M	126 M	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	127 M	118 M	115 M	126 M	146 M	104 M	182 M	109 M	135 M	168 M	190 M	188 M	188 M	188 M	11.2 M	59.6 M	59.6 M	59.6 M	126 M	126 M	126 M	126 M	158 M	158 M	158 M	158 M	74.9 M	74.9 M	74.9 M	74.9 M	150 M	150 M	150 M	150 M	119 M	119 M	119 M	119 M	8.53 M	-	-	-	3.7 M	-	-	-	-	-	-	-
Book Value	357 M	412 M	442 M	475 M	507 M	427 M	454 M	270 M	297 M	301 M	335 M	335 M	335 M	335 M	-21.3 M	65.6 M	65.6 M	65.6 M	135 M	135 M	135 M	135 M	237 M	237 M	237 M	237 M	227 M	227 M	227 M	227 M	262 M	262 M	262 M	262 M	78.7 M	78.7 M	78.7 M	78.7 M	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	357 M	412 M	442 M	475 M	507 M	427 M	454 M	270 M	297 M	301 M	335 M	335 M	335 M	335 M	-41.1 M	65.6 M	65.6 M	65.6 M	-681 K	135 M	135 M	135 M	237 M	237 M	237 M	237 M	227 M	227 M	227 M	227 M	262 M	262 M	262 M	262 M	-61.3 M	-61.3 M	-61.3 M	-61.3 M	-38.8 M	-	-	-	-27.7 M	-	-	-	-	-	-	-

All numbers in USD currency